title: [Response to adjuvant therapy with potassium perchlorate in amiodarone-induced thyrotoxicosis: observations on three cases].
abstract: BACKGROUND
  Amiodarone-induced thyrotoxicosis (AIT) is a common clinical disorder that may be life threatening and whose clinical manifestations and response to treatment may vary among patients.
  
  
  METHODS
  We present three patients treated with amiodarone for atrial fibrillation who developed AIT at least 36 months after beginning the treatment. Thyrotoxicosis worsened the underlying cardiac disorders and was resistant to treatment based on the combination of dexamethasone 8-12 mg/day i.v., thioamides 45 mg/day p.o., beta blockers and potassium perchlorate at doses of 800 to 1000 mg per day p.o. Two of the patients attained sustained euthyroidism after 12 and 32 days of combined treatment, while the third required total thyroidectomy.
  
  
  CONCLUSIONS
  The combination of thioamides with potassium perchlorate is an appropriate form of therapy for AIT in patients resistant to thioamides. The use of this combination should be evaluated in patients with mixed AIT or AIT of unclear etiology.
authors.affiliation: Sección de Endocrinología y Nutrición, Hospital General Universitario de Alicante, Alicante, España. Nieves@socue.es
authors.forename: Nieves
authors.initials: N
authors.lastname: Arias
authors.forename: Óscar
authors.initials: Ó
authors.lastname: Moreno-Pérez
authors.forename: Evangelina
authors.initials: E
authors.lastname: Boix
authors.forename: Joaquín
authors.initials: J
authors.lastname: Serrano
authors.forename: Paula
authors.initials: P
authors.lastname: Revert
authors.forename: Víctor L
authors.initials: VL
authors.lastname: González
authors.forename: Ruth
authors.initials: R
authors.lastname: Sánchez-Ortiga
authors.forename: Antonio M
authors.initials: AM
authors.lastname: Picó
mesh_terms: D000074:Acenocoumarol / Q000008:administration & dosage / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D000638:Amiodarone / Q000009:adverse effects* / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy; D002317:Cardiovascular Agents / Q000627:therapeutic use; D015897:Comorbidity; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010138:Pacemaker, Artificial; D010472:Perchlorates / Q000008:administration & dosage / Q000627:therapeutic use*; D017680:Potassium Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D013854:Thioamides / Q000008:administration & dosage / Q000627:therapeutic use; D013963:Thyroid Hormones / Q000097:blood; D013965:Thyroidectomy; D013971:Thyrotoxicosis / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy* / Q000601:surgery; D013972:Thyrotropin / Q000097:blood
chemical_list: D000319:Adrenergic beta-Antagonists; D002317:Cardiovascular Agents; D010472:Perchlorates; D017680:Potassium Compounds; D013854:Thioamides; D013963:Thyroid Hormones; C009006:potassium perchlorate; D003907:Dexamethasone; D013972:Thyrotropin; D000074:Acenocoumarol; D000638:Amiodarone